Table 5.
Comparing the ICU patients in the B12 study and ICU patients who did not have a B12 measurement at baseline.
| Variable | B12 study (N=1684) | Not in B12 study (N=22,814) | P-value |
|---|---|---|---|
| 30-day mortality | 298 (17.7) | 3049 (13.4) | <0.0001 |
| 90-day mortality | 393 (23.3) | 3845 (16.9) | <0.0001 |
| Age, years | 67.7 (55.4, 78.1) | 65.1 (51, 77.7) | <0.0001 |
| Female | 677 (40.2) | 9918 (43.5) | 0.0087 |
| Race | <0.0001 | ||
| White | 1211 (71.9) | 15713 (68.9) | 0.0094 |
| Black | 159 (9.4) | 1601 (7) | 0.0003 |
| Other | 314 (18.6) | 5500 (24.1) | <0.0001 |
| Insurance type | <0.0001 | ||
| Insured | 549 (32.6) | 9457 (42.1) | <0.0001 |
| Medicaid/Free/Self-pay | 228 (13.5) | 2583 (11.5) | 0.0131 |
| Medicare | 874 (51.9) | 9833 (43.8) | <0.0001 |
| Other | 33 (2) | 578 (2.6) | 0.1267 |
| Liver function: | |||
| ALT, IU/L | 24 (15, 43) | 25 (16, 46) | 0.0013 |
| AST, IU/L | 29 (20, 58.2) | 30 (20, 63) | 0.1296 |
| TB, mg/dL | 0.6 (0.4, 1.1) | 0.6 (0.4, 1) | 0.9987 |
| ALP, IU/L | 85 (66, 121.2) | 80 (61, 111) | <0.0001 |
| ALB, g/dL | 3.3 (2.8, 3.8) | 3.4 (2.9, 3.9) | <0.0001 |
| PT, seconds | 14.6 (13.3, 16.7) | 13.8 (12.9, 15.5) | <0.0001 |
| Liver disease | 230 (13.7) | 1360 (6) | <0.0001 |
| Liver cancer | 35 (2.1) | 495 (2.2) | 0.8625 |
| SAPS | 12 (8, 16) | 10 (6, 14) | <0.0001 |
| First service Unit | <0.0001 | ||
| CCU | 221 (13.1) | 3659 (16) | 0.0015 |
| CSRU | 401 (23.8) | 4653 (20.4) | 0.0010 |
| MICU | 936 (55.6) | 8175 (35.8) | <0.0001 |
| SICU | 126 (7.5) | 6327 (27.7) | <0.0001 |
| Admission type | <0.0001 | ||
| Elective | 162 (10.1) | 3474 (15.8) | <0.0001 |
| Emergency | 1400 (87.3) | 17581 (79.9) | <0.0001 |
| Urgent | 42 (2.6) | 945 (4.3) | 0.0008 |
| ICU LOS | 2.3 (1.2, 4.8) | 2 (1.1, 4.1) | <0.0001 |
| Hospital LOS | 9 (5, 17) | 7 (4, 12) | <0.0001 |
| Non-liver lab values: | |||
| Creatinine, mg/dL | 1 (0.7, 1.7) | 0.9 (0.7, 1.3) | <0.0001 |
| Hemoglobin, g/dL | 10.2 (9, 11.6) | 11.4 (9.9, 13.1) | <0.0001 |
| Folate, ng/mL | 13.4 (9.6, 19.9) | 15 (10.4, 20) | 0.0053 |
| MCV, ng/mL | 91 (86, 96) | 89 (86, 93) | <0.0001 |
| Procedures: | |||
| B12 supplement | 74 (4.4) | 298 (1.3) | <0.0001 |
| Dialysis | 174 (10.3) | 808 (3.5) | <0.0001 |
| TPN | 36 (2.1) | 467 (2) | 0.7892 |
| Inotropic support | 366 (21.7) | 3557 (15.6) | <0.0001 |
| Comorbidities: | |||
| Alcoholism | 300 (17.8) | 791 (3.5) | <0.0001 |
| Sepsis | 276 (16.4) | 2217 (9.7) | <0.0001 |
| Respiratory disease | 220 (13.1) | 2641 (11.6) | 0.0704 |
| Myeloproliferative disease | 11 (0.7) | 85 (0.4) | 0.1002 |
| Stroke | 134 (8) | 2569 (11.3) | <0.0001 |
| CAD | 631 (37.5) | 7553 (33.1) | 0.0003 |
| Other CVD | 978 (58.1) | 11610 (50.9) | <0.0001 |
| Hypertension | 862 (51.2) | 10767 (47.2) | 0.0016 |
| Immunocompromised | 474 (28.1) | 1474 (6.5) | <0.0001 |
| Neuro-psychiatric disorder | 533 (31.7) | 5847 (25.6) | <0.0001 |
| GI hemmorrhage | 93 (5.5) | 766 (3.4) | <0.0001 |
Data presented as number (%) or median (inter-quartile range).